Markets
markets

Lululemon gets hammered, down 21% after cutting its full-year profit outlook

Lululemon sweats might be comfortable, but its second-quarter outlook is not.

Shares of the upscale athletic-wear company plunged more than 21% after the bell following its earnings report Thursday.

Lulu guided for second-quarter revenue of between $2.54 billion and $2.56 billion, shy of Wall Street’s estimate of $2.57 billion, and it forecast earnings per share of $2.85 to $2.90, far below analysts’ expectations of $3.29. The company cut its full-year EPS outlook to between $14.58 and $14.78. It had previously expected $14.95 to $15.15.

CEO Calvin McDonald nodded to the “dynamic macroenvironment” (i.e. tariffs and their impact). Lululemon rival and Athleta owner Gap last week said it expects a tariff hit of up to $150 million this year.

More Markets

See all Markets
markets

Grail rises after announcing $325 million raise from Hims, others

Grail, a cancer detection biotech, rose more than 20% after it announced that it raised $325 million from a slate of investors including Hims & Hers.

Grail sells a blood test that detects cancerous tumors early on. The company also announced encouraging trial results for its flagship test, Galleri, on Friday.

Grail sold 4,639,543 shares at $70.05, a discount from the $78 closing price on Friday, to a group of more than six investors. Hims did not immediately respond to questions from Sherwood News, including how much of the $325 million fundraise it contributed. Grail announced last week that it received a $110 million investment from Samsung.

Grail reported $67.4 million in revenue in the first half of this year, up from $58.6 million in the same period in 2024. Galleri is available commercially but is pending approval from the Food and Drug Administration, which could position it to be covered by major insurers.

markets

AppLovin sinks amid report that multiple state regulators are looking into its data collection practices

Shares of adtech company AppLovin are on their back foot to open the week on the heels of a report from the New York Post that “state regulators, including staff from the attorneys general from Delaware, Oregon and Connecticut, have reached out to multiple short sellers, seemingly as part of a preliminary investigation.”

AppLovin told the Post that it is “not engaged in any investigations with any state attorneys general regarding its business; nor has the Company been contacted by any state attorneys general regarding any such alleged investigation.”

AppLovin got whacked earlier this month after Bloomberg reported that its data collection practices are the subject of an SEC probe. While they initially bounced after Wall Street suggested selling in response to the news was overdone, they’ve since proceeded to hit fresh lows even after AppLovin said that it had shut down software that short sellers alleged was responsible for installing apps on users’ phones without their permission.

markets

Opendoor price target raised to a Wall Street high of $6 at Morgan Stanley

Morgan Stanley analysts raised their price target on Opendoor Technologies to the highest on Wall Street. However... they’re still not actually bullish on the online real estate company.

In a wide-ranging note on internet stocks as the Q3 earnings season heats up, analysts Brian Nowak and Matthew Cost (who covers Opendoor) wrote:

“While we see limited fundamental justification for OPEN’s recent outperformance, we also see the opportunity for a pivot back to home-buying (and significant operating leverage) should there be a stronger housing market recovery. Moreover, similar situations with other stocks have shown that higher valuations are not only often more sustainable than expected, but also create the opportunity for companies to raise capital and address challenges with the support of an enthusiastic shareholder base. With that in mind we mark our base case price target to market at $6.”

Morgan Stanley’s previous price target was $2. Analysts kept their “market perform” (or “hold”) rating on the company intact.

The obvious corollary here is GameStop, a company that has had a high value ascribed to the value of its cash based on the idea that CEO Ryan Cohen would be able to do a lot to transform the company with that money. Opendoor bulls are similarly enthused by the company’s turnaround prospects under its new management. Its biggest one-day gain on record came after news that cofounders Keith Rabois and Eric Wu were being added to the board of directors and that Shopify COO Kaz Nejatian was coming in to serve as CEO.

GameStop, without doing anything too revolutionary, has managed to turn around its business since its initial run as a meme stock, and has now strung together five consecutive quarters of positive operating cash flows for the first time in its history.

The sell side is pretty downbeat on Opendoor, with just one “buy” (or “buy equivalent), five “hold,” and five “sell” ratings among analysts tracked by Bloomberg.

markets

Moderna rises on study suggesting COVID-19 shot enhances efficacy of cancer treatment

Moderna rose more than 5% on Monday after a new study showed that mRNA COVID-19 shots could enhance cancer immunotherapy.

The results were presented by researchers from MD Anderson Cancer Center at the European Society for Medical Oncology conference in Berlin on Sunday, Stat News and others reported. The study found that cancer patients who took the COVID-19 shot within 100 days of taking an immunotherapy drug lived longer.

Moderna was tapped by the first Trump administration alongside Pfizer to quickly develop an immunization for Covid in 2020. Moderna still makes nearly all of its revenue from the vaccine while Pfizer has a larger, more diversified portfolio. Moderna has other products in its pipeline, including a dual flu and COVID-19 vaccine and personalized cancer vaccines.

markets

Apple is at an all-time high

Apple is trading at an intraday all-time high stock price of $263.50 as of 11:45 am EST, after an upgrade from Loop Capital to a Street high price target of $315 and following positive sales growth indicators for its iPhone 17.

Apple’s all-time close was $259.02 on December 24, 2024, the same day as its last intraday high. Analysts expect iPhone revenue to return to growth this year and next.

Latest Stories

Sherwood Media, LLC produces fresh and unique perspectives on topical financial news and is a fully owned subsidiary of Robinhood Markets, Inc., and any views expressed here do not necessarily reflect the views of any other Robinhood affiliate, including Robinhood Markets, Inc., Robinhood Financial LLC, Robinhood Securities, LLC, Robinhood Crypto, LLC, or Robinhood Money, LLC.